nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-1340Research ArticleШКОЛА НЕФРОЛОГАEDUCATIONAL MATERIALSГенетическая гипергомоцистеинемия как причина артериальных и венозных тромбозов у больного хроническим гломерулонефритомGenetic hyperhomocysteinemia as a cause of arterial and venous thrombosis in a patient with chronic glomerulonephritisБаранниковаЕ. И.BarannikovaE. I.noemail@neicon.ruКозловскаяН. Л.KozlovskayaN. L.noemail@neicon.ruПонкинаО. Н.PonkinaO. N.noemail@neicon.ruСеменченкоН. А.SemenchenkoN. A.noemail@neicon.ruОтделение нефрологии и диализа Краевой клинической больницы № 1 им. профессора С.В. Очаповского, Уронефрологический центр, г. КраснодарRussian Federationкафедра нефрологии и гемодиализа ММА им. И.М. СеченоваRussian Federation200819062025103-4254258Copyright © Баранникова Е.И., Козловская Н.Л., Понкина О.Н., Семенченко Н.А., 20252025Баранникова Е.И., Козловская Н.Л., Понкина О.Н., Семенченко Н.А.Barannikova E.I., Kozlovskaya N.L., Ponkina O.N., Semenchenko N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/1340

Генетическая гипергомоцистеинемия (ГГц), в большинстве случаев обусловленная полиморфной мутацией гена метилентетрагидрофолатредуктазы (МТГФР) С 677Т, является фактором риска артериальных и венозных тромбозов. Приводимое наблюдение иллюстрирует возможность одновременного развития тромбоза нижней полой, обеих почечных и левой общей подвздошной вен и ишемического инсульта у молодого пациента с ГГц и нефротическим вариантом хронического гломерулонефрита (ХГН).

Inherited hyperhomocysteinemia in most cases results from a mutation in gene MTHFR C677T. It is a risk factor of both arterial and venous thromboses. A case is described where thrombosis in vena cava inferior, in both renal and left ileofemoral veins and ischemic cerebral infarction have been developed simultaneously in a young man with inherited hyperhomocysteinemia and chronic nephrotic glomerulonephritis.

гомоцистеингипергомоцистеинемиягломерулонефритнефротический синдромтромбозыReferencesКозловская Н.Л., Медведева Т.Ю., Мирошниченко Н.Г., Камалов Ю.Р. Тромбоз почечных вен при мембранозной нефропатии. Терапевт. архив 2000; 6: 71-73.Козловская Н.Л., Медведева Т.Ю., Мирошниченко Н.Г., Камалов Ю.Р. Тромбоз почечных вен при мембранозной нефропатии. Терапевт. архив 2000; 6: 71-73.Austin R.C., Lentz S.R., Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Сеll Death Differ 2004; 11: S56-S64.Austin R.C., Lentz S.R., Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Сеll Death Differ 2004; 11: S56-S64.Bellamy M.F., McDowell I.F., Ramsey M.W. Hyperhomocysteinemia after аn оrаl methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-1852.Bellamy M.F., McDowell I.F., Ramsey M.W. Hyperhomocysteinemia after аn оrаl methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-1852.Bellomo R., Atkins R.C. Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted? Nephron 1993; 6: 249-254.Bellomo R., Atkins R.C. Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted? Nephron 1993; 6: 249-254.Boushey C.J., Beresford S.A.A., Omenn G.S. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.Boushey C.J., Beresford S.A.A., Omenn G.S. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.Chambers J.C., McGregor D., Jean-Marie J. et al. Demonstration of rapid inset vascular endothelial dysfunction after hyperhomocysteinemia and effect reversible with vitamin С therapy. Circulation 1999; 99: 1156-1160.Chambers J.C., McGregor D., Jean-Marie J. et al. Demonstration of rapid inset vascular endothelial dysfunction after hyperhomocysteinemia and effect reversible with vitamin С therapy. Circulation 1999; 99: 1156-1160.Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 2005; 5: 215-222.Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 2005; 5: 215-222.Fryer R.H., Wilson B.D., Gubler D.B. et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induced tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-1333.Fryer R.H., Wilson B.D., Gubler D.B. et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induced tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-1333.Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis J Clin Invest 1976; 58: 731-741.Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis J Clin Invest 1976; 58: 731-741.Den Heijer M., Koster T., Blom H.K. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.Den Heijer M., Koster T., Blom H.K. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002; 288: 2015-2022.Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002; 288: 2015-2022.Lee R., Frenkel Е.Р. Hyperhomocysteinemia and thrombosis. Hematol Опcol Clin North Аm 2003; 17: 85-102.Lee R., Frenkel Е.Р. Hyperhomocysteinemia and thrombosis. Hematol Опcol Clin North Аm 2003; 17: 85-102.Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-439.Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-439.Meroni P.L., Riboldi P. Pathogenetic mechanism mediating antiphospholipid syndrome. Curr Opin Rheumatol 2001; 13: 377-382.Meroni P.L., Riboldi P. Pathogenetic mechanism mediating antiphospholipid syndrome. Curr Opin Rheumatol 2001; 13: 377-382.Ozaras R., Mete B., Hakko E. et al. Primary antiphospholipid syndrome: a cause of fever of unknown origin. Intern Med 2003; 42: 358-361.Ozaras R., Mete B., Hakko E. et al. Primary antiphospholipid syndrome: a cause of fever of unknown origin. Intern Med 2003; 42: 358-361.Perutelli P., Amato S., Minniti G., Bottini F., Calevo M.G., Cerone R., Molinari A.C. Von Willebrand factor multimer composition is modified following oral methionine load in women with thrombosis, but not in healthy women. Blood Coagul Fibrinolysis. 2005; 16: 267-273.Perutelli P., Amato S., Minniti G., Bottini F., Calevo M.G., Cerone R., Molinari A.C. Von Willebrand factor multimer composition is modified following oral methionine load in women with thrombosis, but not in healthy women. Blood Coagul Fibrinolysis. 2005; 16: 267-273.Rabelink T.J., Zwaginga J.J., Koomans H.F., Sixma J. Thrombosis and hemostasis in renal disease Kidney Int 1994; 46: 287-296.Rabelink T.J., Zwaginga J.J., Koomans H.F., Sixma J. Thrombosis and hemostasis in renal disease Kidney Int 1994; 46: 287-296.Rosen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylentetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523-526.Rosen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylentetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523-526.Roubey R.A.S. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7: S114-S119.Roubey R.A.S. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7: S114-S119.Sauls D.L., Lockhart E., Warren M.E. et al. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 2006; 45 (8): 2480-2487.Sauls D.L., Lockhart E., Warren M.E. et al. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 2006; 45 (8): 2480-2487.Tsai J.C., Perrella М.А., Yoshizumi М. et al. Promotion of vascular smooth muscle сеll growth bу homocysteine: а link to atherosclerosis. Рrос Natl Acad Sci USA 1994; 91: 6369-6373.Tsai J.C., Perrella М.А., Yoshizumi М. et al. Promotion of vascular smooth muscle сеll growth bу homocysteine: а link to atherosclerosis. Рrос Natl Acad Sci USA 1994; 91: 6369-6373.Welch G.N., Loscalso J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.Welch G.N., Loscalso J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.Welch G.N., Upchurch G.R.J., Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract 1997; 32: 81-82.Welch G.N., Upchurch G.R.J., Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract 1997; 32: 81-82.

The authors declare that there are no conflicts of interest present.